A five-gene TAM and MYCN signature predicts prognosis and identifies MTHFD2 as a therapeutic target in neuroblastoma.

Discov Oncol · 2026 · PMC13438019 · PMID 42550464

Europe PMC DOI

hedged sentence

0.0140

closest p · 0.3× alpha

0.0140

boldest claim

The sentences

not as significantP = 0.014actually significant

3 B, D, indicated that, although the advantage in OS and EFS for the low-risk group over the high-risk group was not as significant as in the internal training group, it still showed a statistically significant difference ( P = 0.014 and P = 0.033).

also in 143 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.